Circular instead of hierarchical: methodological principles for the evaluation of complex interventions by Walach, Harald et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Medical Research 
Methodology
Open Access Debate
Circular instead of hierarchical: methodological principles for the 
evaluation of complex interventions
Harald Walach*1, Torkel Falkenberg2, Vinjar Fønnebø3, George Lewith4 and 
Wayne B Jonas5
Address: 1University of Northampton & Samueli Institute – European Office, School of Social Sciences, Park Campus, Northampton NN2 7AL, 
UK, 2Karolinska Institutet, Center for Studies of Complementary Medicine, Department of Public Health Sciences, Division of International Health 
(IHCAR) and Department of Nursing, Stockholm, Sweden, 3National Research Center in Complementary and Alternative Medicine, University of 
Tromsø, Tromsø, Norway, 4University of Southampton, Department of General Practice, Southampton, UK and 5Samueli Institute, Alexandria VA, 
USA
Email: Harald Walach* - harald.walach@northampton.ac.uk; Torkel Falkenberg - Torkel.Falkenberg@ki.se; 
Vinjar Fønnebø - Vinjar.Fonnebo@fagmed.uit.no; George Lewith - gl3@soton.ac.uk; Wayne B Jonas - wjonas@siib.org
* Corresponding author    
Abstract
Background:  The reasoning behind evaluating medical interventions is that a hierarchy of
methods exists which successively produce improved and therefore more rigorous evidence based
medicine upon which to make clinical decisions. At the foundation of this hierarchy are case studies,
retrospective and prospective case series, followed by cohort studies with historical and
concomitant non-randomized controls. Open-label randomized controlled studies (RCTs), and
finally blinded, placebo-controlled RCTs, which offer most internal validity are considered the most
reliable evidence. Rigorous RCTs remove bias. Evidence from RCTs forms the basis of meta-
analyses and systematic reviews. This hierarchy, founded on a pharmacological model of therapy,
is generalized to other interventions which may be complex and non-pharmacological (healing,
acupuncture and surgery).
Discussion: The hierarchical model is valid for limited questions of efficacy, for instance for
regulatory purposes and newly devised products and pharmacological preparations. It is inadequate
for the evaluation of complex interventions such as physiotherapy, surgery and complementary and
alternative medicine (CAM). This has to do with the essential tension between internal validity
(rigor and the removal of bias) and external validity (generalizability).
Summary: Instead of an Evidence Hierarchy, we propose a Circular Model. This would imply a
multiplicity of methods, using different designs, counterbalancing their individual strengths and
weaknesses to arrive at pragmatic but equally rigorous evidence which would provide significant
assistance in clinical and health systems innovation. Such evidence would better inform national
health care technology assessment agencies and promote evidence based health reform.
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Background
The hierarchical view of evaluation of medical 
interventions
Evidence Based Medicine (EBM) has installed a canon of
methods that are central to the methodological reasoning
for evaluating medical interventions [1]. While originally
developed for the evaluation of new pharmacological
products [2,3], it is also applied to whole systems inter-
vention approaches like nursing and psychotherapy, as
well as the more complex interventions of Complemen-
tary and Alternative Medicine (CAM). EBM's main tool is
the randomized controlled trial (RCT). Its essential prin-
ciple is random assignment of a sufficiently large number
of carefully selected patients to experimental and control
groups, thereby evenly distributing known and unknown
confounding variables. Changes in outcome can thus be
attributed to the intervention(s).
A hierarchy of methods has been described and utilized by
health technology assessment (HTA) agencies, with case
series, cohort studies with historical controls, non-rand-
omized controlled studies being of lower value and hav-
ing less methodological rigor than prospective RCTs. Only
RCTs are considered for inclusion in many meta-analyses
and systematic reviews. These form the theoretical, if often
abused and misunderstood, basis for EBM and the clinical
decision making process.
We would like to argue for a broader, circular view that
illustrates the equivalence of research methods in non-
pharmacological interventions. More specifically we will
argue that there is no such thing as a single inherently
ideal methodology. There are different methods to answer
different questions, all of which come together in a
mosaic [4] or evidence house [5]. A poorly designed and
badly implemented RCT is, as a rule, less valuable than
well conducted studies using other designs, and some-
times even non-randomized studies can produce more
reliable and useful information than a well conducted
randomized study.
Discussion
Assumptions and problems of the hierarchical view
The hierarchical view makes some important assumptions
which are not universally valid but rarely debated (Table
1) [6,7]. All of these assumptions are problematic and
sometimes false in complex interventions. They are useful
for the evaluation of new pharmacological agents but
even in that situation often only some of the assumptions
are met.
Problems with the assumptions
1. Preference and clinical equipoise
Equipoise is traditionally the most important precondi-
tion for conducting RCTs. It means that there is no prefer-
ence based on systematic knowledge for a treatment over
an alternative or no treatment. Clinical equipoise is con-
sidered most important. It refers to the notion that there
is honest disagreement about the optimal treatment
among the medical community or between important sec-
tors of the community. Equipoise is normally fulfilled
with new procedures or pharmacological agents entering
phase III studies. The RCT was introduced in exactly this
context initially [2,3,8,9]. There are many practices in
medicine which do not follow the rationale of a pharma-
cological intervention or which are more complex. Nurs-
ing and caring systems, traditional healing systems, CAM,
life-style and psychological interventions, as well as sur-
gery and rehabilitation are only some examples of com-
plex treatments. In these interventions a whole array of
therapeutically active elements may be operating simulta-
neously and synergistically. It is therefore impossible to
imply a pre-trial equipoise. This is usually the case for doc-
tors who have undergone considerable training in special-
ized disciplines which themselves are founded on their
own bodies of evidence. This lack of equipoise is one of
the main obstacles to a systematic evaluation of surgical
interventions with RCTs [10].
2. Knowledge
This has to do with the influence of a large body of histor-
ical unsystematic experience within the surgical or CAM
context and elsewhere. The body of historical and non-
systematic experience with surgery or CAM is not consid-
ered a sufficient scientific argument for efficacy but also
does not preclude systematic research. It does, however,
alter clinical equipoise. Therefore, patients willing to be
enrolled in a surgical or CAM study may be different from
those actively seeking out such treatments. If belief and
positive expectations are important factors in enhancing
Table 1: Assumptions made in conducting randomized controlled trials
Equipoise Patient and provider do not have a preference for a treatment
Lack of knowledge It is truly unknown which of two alternatives is "better" and there is insufficient evidence about 
treatment effects from other sources
Preference for specificity Only specific effects attributable to the intervention are therapeutically valid
Context independence There is a "true" magnitude of efficacy, or a stable effect size independent of context
Ecological and external validity 
knowable
The knowledge about a therapeutic effect extracted from an RCT is readily transferable into clinical 
practice, if exclusion and inclusion criteria of the trial match the characteristics of a given patientBMC Medical Research Methodology 2006, 6:29 http://www.biomedcentral.com/1471-2288/6/29
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treatment effects or even generating the preconditions for
such treatment effects, then outcomes from trials where
patient preference or treatment expectations are not con-
sidered are unrealistic estimators for the effects likely to
occur in uncontrolled practice. Therefore failure to find an
effect in a randomized trial cannot necessarily be taken as
an indication of ineffectiveness. As a consequence, the
outcomes gathered from rigorous and methodologically
sound trials may not be generalizable to users within the
community. Preliminary evidence from unsystematic
experience and patient or provider preferences are
strongly linked. The "stronger" and "older" the experi-
ence, the more embedded in our culture, the more it may
be leading to patient and provider preferences thus alter-
ing equipoise, expectation and outcome.
3. Specificity
One important and rarely discussed assumptions for
RCTs, especially placebo-controlled RCTs is specificity. It
refers to the assumption that the only worthwhile effects
are attributable to an understandable mechanism that can
be clearly ascribed to a specific component of an interven-
tion. The presupposition that only specific effects are val-
uable is untrue, particularly from the patient's perception.
It leads to what has been called the efficacy paradox [11].
The efficacy paradox can come into play whenever com-
plex interventions are tested against a control procedure
and the control procedure implies some form of complex
intervention. It can even be important in seemingly sim-
ple placebo controlled trials. This is illustrated in Fig. 1.
Consider two treatments, x and y, both tested in two con-
trolled RCTs for efficacy. Suppose that treatment x has,
overall, 70% effect, while treatment y has 55% effect in
the same disease. Moreover, let us suppose that treatment
x does not have a significant effect over control, or placebo
x, while treatment y does. This is, because treatment y has
a stronger specific effect than treatment x. Although this is,
at least in principle, a matter of statistical power, let us
suppose that the specific effects of treatment x are so small
that they have escaped detection so far, while the general
effects – specific and non-specific together – of treatment
x are powerful. This leads to the efficacy paradox: A treat-
ment that is efficacious – treatment y – can be less effective
than a treatment whose efficacy has not been shown sta-
tistically different from control treatment(s) – treatment x.
Research has focused only on the difference between the
treatment condition and the control in an attempt to iso-
late the magnitude of the specific components of treat-
ment, thereby neglecting the overall treatment effect. It is
the latter which is most interesting to patients [12-15]. It
might even be the case that the full therapeutic benefit can
only be achieved in a setting that does not attempt to iso-
late any part of the effect, and hence trials designed to esti-
Illustration of the Efficacy Paradox Figure 1
Illustration of the Efficacy Paradox. Treatment x can have a larger overall effect than treatment y, although only treatment y 
shows a sizeable and significant specific treatment effect; specific = specific component of treatment; non-specific = non-specific 
component of treatment; regression = regression to the mean, natural regression of the disease; artefacts = measurement 
artefacts that mimic therapeutic effects; non-specific effects, artefacts, and regression comprise the placebo effect in RCTs.
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mate the specific component of a treatment effect will fail
to evaluate the full therapeutic benefit. Since placebo con-
trolled RCTs are designed to isolate specific components
they may be contraindicated in situations where the spe-
cific effects are likely to be small but the whole treatment
effect large due to a complex interaction of specific and
nonspecific effects [15-19].
What has been described above as a theoretical scenario
has actually been empirically demonstrated meanwhile:
The GERAC study (German acupuncture trial), the hith-
erto largest acupuncture trial, tested real acupuncture ver-
sus minimal acupuncture as a control procedure, versus
pharmacological prophylaxis in migraine patients as an
active treatment. This trial showed no difference between
acupuncture and control, thus "proving" the "inefficacy"
of acupuncture. However it also demonstrated that con-
ventional pharmacological prophylaxis, normally consid-
ered efficacious, was not only not different from the
acupuncture control, but in some secondary parameters
and analyses even significantly worse than the supposedly
ineffective acupuncture procedure thus illustrating the
efficacy paradox [20]!
The paradox is obvious and runs thus: 1. Pharmacological
prevention of migraine is considered efficacious after dec-
ades of research. 2. Sham acupuncture is not considered
efficacious. In fact, it was included as a control condition.
3. The efficacy of acupuncture was contested. Hence a trial
should either show superiority of the already proven
intervention, pharmacological prevention, over the con-
trol condition, and equality of acupuncture with this effi-
cacious standard treatment. The conclusion would then
be: acupuncture is effective. Or else pharmacological pre-
vention should show superiority over sham acupuncture
and acupuncture, thereby disproving the efficacy of acu-
puncture (and sham acupuncture by default). As it hap-
pens, the conclusion can now only be: none of the
interventions is effective, as none is really significantly dif-
ferent from the control. Hence a known effective interven-
tion, pharmacological prevention, is rendered ineffective
by the strong non-specific effect shown in the sham acu-
puncture (and acupuncture) group, because the logic of
efficacy testing is focusing only on the difference. Clearly,
this is a paradoxical and somewhat silly conclusion, but
one that has to be accepted, if one wishes to live by the
standards of clinical trial testing.
4. Context dependence
Evidence is accumulating that the current assumptions
about independence of context and setting are wrong: In
two very similar trials of paracetamol, one against pla-
cebo, one against naproxen in postpartum pain, paraceta-
mol had twice the effect in alleviating pain when subjects
were expecting active treatment than when tested against
placebo [21-23]. The expectancy of patients does modu-
late therapeutic effects so that pharmacological and psy-
chological components are inseparable [24,25].
Naproxen under trial conditions has been reported to be
significantly more effective than naproxen under normal
bedside conditions, and in addition, placebo under trial
conditions was more effective than naproxen under nor-
mal conditions [26]. A meta-analysis of the effects of
interactions between medications and context effects
found that pharmacological effects can sometimes be
changed dramatically as a consequence of contextual ther-
apeutic messages and beliefs. Pharmacological effects are
not a stable quantity [27]. Context can be kept constant in
a trial to determine efficacy and can be modulated
through a variety of factors in the clinical setting, such as
the belief of providers and patients [28], attitude and
demeanor of the doctor [29,30], enthusiasm for the deliv-
ery of the intervention [31,32], cultural contexts and con-
comitant suggestions regarding diet and health [33,34].
These contextual effects can be so strong and variable that
they completely overshadow the pharmacological effects
of selective serotonin re-uptake inhibitors (SSRIs) [35].
Expectancy of patients seems a key factor [36,37] that has
been shown to modulate therapeutic effects of anti-emetic
treatments in chemotherapy [38-42] and of massage in
low back pain [43,44]. Taken together these results sug-
gest that the assumption of a "true" magnitude of a thera-
peutic effect, independent of context, is a very flawed
construct.
5. Ecological and external validity
The last assumption posits that internal validity is not
only a necessary but also a sufficient condition for exter-
nal validity or generalizability. An important question not
answered by an RCT is that of clinical applicability: Are
the effect sizes observed in an RCT reduplicated in an
open clinical study? RCTs are only externally valid for the
type of patients included in the trial. For an observation to
be generalizable, the proportion of patients accrued for
the trial must be comparatively large and representative of
the condition in the community. This condition is fre-
quently not met [7]. Depending on the intervention and
the disease, patients enrolled in trials may be different
from patients in clinical practice [6,45-47], primarily
because selection criteria in clinical trials often do not
properly reflect clinical practice [10,48,49] Selection bias
could occur because the willingness to participate in a trial
may be associated with certain types of patient character-
istics [50]. Such a selection bias could lead to an overesti-
mation of effects [51] if participants in trials are more
positive towards the interventions than non-participants
[52,53] The assumption that results of RCTs are generaliz-
able to clinical practice is commonly made, rarely tested,
and if empirically studied, often not warranted [54]. One
solution proposed to solve this dilemma is large multicen-BMC Medical Research Methodology 2006, 6:29 http://www.biomedcentral.com/1471-2288/6/29
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tre trials with thousands of participants and very few
inclusion criteria [55]. However, they do not seem to be
more reliable in estimating effects [56,57] than smaller
studies, while at the same time they are costly and compli-
cated. Furthermore, even mega-trials cannot test for the
effect of free choice of a therapeutic method on health
outcome.
If we take into account the context dependence of thera-
peutic effects, then it is clear that each study creates its
own little universe of applicability which in the best case
is an abstraction and in the worst case a distortion of the
real world of clinical practice. Ecological validity is ham-
pered the more the experimental control alters the context
of clinical delivery, patient choice, and patient eligibility
compared to normal practice. Thus, experimental control,
while enhancing internal validity, jeopardizes external
and ecological validity by default.
The circular model of evaluation
The alternative to the hierarchical model is a circular one.
It is derived from the experience and history of evaluation
methodology in the social sciences [58-62], which has
reached the consensus that only a multiplicity of meth-
ods, which are used in a complementary fashion will
eventually give a realistic estimate of the effectiveness and
safety of an intervention. Every research method has
strengths and weaknesses which cannot be resolved
within that method itself. Therefore, triangulating a result
achieved with one method by replicating it with other
methods may provide a more powerful and comprehen-
sive approach to EBM when compared to the prevailing
RCT approach. Rather than postulating a single "best
method" this view acknowledges that there are optimal
methods for answering specific questions, and that a com-
posite of all methods constitutes best scientific evidence
(Fig. 2).
The important point is not whether a study is randomized
or not, but whether it uses a method well suited to answer
a question and whether it implements this method with
optimal scientific rigor. Figure 2 illustrates this situation:
methods that are high in internal validity, such as placebo
controlled RCTs or active comparator RCTs tend to be
lower in external validity [63]. Thus their results need to
be balanced by large and long term observational studies
which document the use, safety and effectiveness of the
intervention in clinical practice [64,65]. In order to assess
whether an intervention has the same effect in a relevant
clinical population as it does in an RCT, comparative stud-
ies in pragmatically selected cohorts are essential. If rand-
omization proves difficult or impossible, such studies
may be the only ones possible. There is some evidence
that cohort studies produce effect size estimations compa-
rable to RCTs, if conducted properly [66-68]. However, we
must address the issue of variability and divergence in
non-randomized studies and how this should be man-
aged [69]. If it is enough to document effects as different
from the natural course of the disease, a waiting list con-
trolled RCT is an option. Since the intervention can be
studied in its natural setting without any distortion
through blinding or other restrictions, results are fre-
quently more representative of what happens in clinical
practice. Waiting list controls of up to six months are fea-
sible in our experience depending on the condition [70].
In some cases even retrospective audits of large, well doc-
umented data sets, or better prospective documentations
of pragmatically treated cohorts might give useful infor-
mation about effectiveness. Single-group observational
studies, in certain circumstances and with large numbers,
can also yield important information [71]. If the interven-
tion is a novel pharmacological agent, regulatory
demands request that efficacy is established first, subse-
quent to phase 1 and phase 2 trials.
Circle of methods Figure 2
Circle of methods. Experimental methods that test specifi-
cally for efficacy (upper half of the circle) have to be comple-
mented by observational, non-experimental methods (lower 
half of the circle) that are more descriptive in nature and 
describe real-life effects and applicability. The latter can range 
from retrospective audit studies, prospective case series to 
one armed to multiple armed cohort studies. Matched pairs 
studies can be conducted as experimental studies, by forming 
first pairs and then randomizing them, or as quasi-experi-
mental studies by forming pairs from naturally occurring 
cohorts according to matching criteria. Shading indicates the 
complementarity of experimental and quasi-experimental 
methods, of internal and external validity.BMC Medical Research Methodology 2006, 6:29 http://www.biomedcentral.com/1471-2288/6/29
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Finally, broad applicability, acceptability and a complete
safety profile is established in large single-group observa-
tional trials. The previous sequence is a typical example of
the steps necessary to test newly developed interventions
for efficacy, applicability and safety. It has been observed
that with already established interventions, such as with
some CAM procedures which have a long tradition, e.g.
acupuncture or homeopathy, and also with well estab-
lished but little researched complex interventions such as
surgical or rehabilitation procedures, the evaluation proc-
ess is reversed [72]: Here, one wants to know about gen-
eral clinical effectiveness and safety first. Only if this is
established, are other studies warranted that probe spe-
cific efficacy, and subsequently we then develop our
understanding of the underlying mechanisms of action.
There are many treatments within clinical practice, where
general effectiveness was established first, and specific
efficacy or mechanisms of actions were discovered only
later on, such as the use of aspirin, penicillin or the West-
ern model of acupuncture. In cases where treatments have
been in use for some time, the rational evaluation method
starts at the non-experimental side of the circle. Thus,
effect sizes will have to be established not only with the
one preferred method, the RCT, but with different
approaches. If convergence of effect size estimates is
reached through this strategy, one can be reasonably sure
about the evidence of effectiveness. If different methods
have produced different results and effect size estimates,
unknown moderator variables and confounding may be
present. These could be the selective effectiveness of an
intervention for certain subgroups. As in meta-analysis,
where significant variation of effect size estimates is taken
as an indicator of inhomogeneity, a lack of convergence of
effect sizes in a circular strategy would be taken as an indi-
cator of moderating influences which have to be explored.
Gabbay and Le May [1] found in their ethnographic study
of decision-making in general practice that clinical deci-
sion-making is based on a combination of evidence-based
medicine including systematic reviews and meta-analyses,
clinical experience, individual patient need, patient and
practitioner preference and peer group advice. This empir-
ical finding supports our argument by a description of
how clinicians actually come to a decision: The pyramidal
hierarchy of conventional evidence-based medicine is
rarely the only basis upon which clinical decisions are
based in real life, primarily because such process-driven
management systems almost always fail to take into
account our individual nature, personal values and prefer-
ences of patients. Thus, decision making in real-life is
actually much more circular than the prescriptive hierar-
chy of EBM would have us believe [1].
For example, many patients recover because of complex,
synergistic or idiosyncratic reasons that cannot be isolated
in controlled environments. The best evidence in such
cases is observational data from specific clinical practices
that estimates the likelihood of a patient's recovery in that
practice setting. In other cases the most important infor-
mation may be a highly subjective judgment about life
quality. These very personal experiences of illness can
only be captured with qualitative research, making this
the best evidence under such circumstances. Sometimes
the best evidence comes from laboratory studies. Data on
the metabolic interaction of anti-virals with the herb
Hypericum is crucial to the management of HIV patients
[73]. Controlled trials cannot usually isolate such interac-
tions and other surveillance methods are required. By
conceptualizing evidence as circular we can highlight the
fact that sometimes the "best" evidence may not be attri-
butional, objective, additive or even clinical [5].
A circle has no preferred orientation. It might be a more
fitting image for clinical research by balancing the weak-
nesses of one method with strengths of another. A hierar-
chy of methods emphasizes internal validity and
experimental evidence, promoting them to a higher prior-
ity than external validity. Rather than constructing two
opposing methodological approaches, one should strive
for complementarity. We suggest that evidence-based
medicine and HTA agencies should confront the reality of
this situation in a formal manner and begin to develop a
consensus-based approach that takes the evidence-based
hierarchy into account, but at the same time is not ruled
solely by it. Circularity, with the attendant flexibility for
individualization, could provide the image describing the
delicate interaction between patient and practitioner with
systematic reviews, RCTs, qualitative reviews, safety, cost
and individual clinical experience, all being important
and recognized elements of each individualized decision-
making process. Their specific importance may vary
according to the individual strength of the evidence, the
risks involved and the condition being treated. It might be
possible for databases such as the Cochrane database to
include not only issues of safety, efficacy and cost, but also
evidence from patient preference and increasingly from
qualitative work. The whole essence of circularity is its
ability to see the whole problem within a patient-centered
and human therapeutic perspective, allowing rigorous
evidence, individualized decision-making at the clinical
interface. We believe this is how both doctors and patients
make clinical decision in the 'real world and consequently
we believe our research processes should reflect this real-
ity.
Summary
We have argued that the widely held view of research
methods forming a hierarchy is at best a simplification, at
worst mistaken. Internal validity has to be balanced by
external validity, and this can rarely be achieved with oneBMC Medical Research Methodology 2006, 6:29 http://www.biomedcentral.com/1471-2288/6/29
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single research method such as the RCT, but involves
other strategies such as outcomes and cohort studies. A
circular and integrative view then develops which sees
research methods as particular pathways for different
questions. All answers combined yield scientific evidence.
Methods, then, should be viewed not in terms of a hierar-
chy of intrinsic worth but as valuable only relative to the
question asked. To answer the question of efficacy and
effectiveness, we need to triangulate different methods to
achieve homogeneity. If this cannot be reached, then
moderator or confounding influences must be investi-
gated. These could be methodological in nature (bias), or
systematic due to differential effectiveness and context.
Such views will change the rationale of medical decision
making by bringing patients, researchers and decision
makers together to develop a patient-centered evidence-
based consensus that will inform clinical decision making
and health care reform.
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